Primary Aldosteronism Prevalence – An Unfolding Story
Experimental and Clinical Endocrinology & Diabetes · 01.08.2023 · 131 (07/08) · 394-401
DOI: 10.1055/a-2066-2696 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.08.2023. Verfasst von Suranut Charoensri und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, USA. Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Hyperaldosteronism, Hypertension. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: NHLBI NIH HHS, Doris Duke Charitable Foundation, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Primary aldosteronism (PA) is characterized by dysregulated, renin-independent aldosterone excess. Long perceived as rare, PA has emerged as one of the most common causes of secondary hypertension. Failure to recognize and treat PA results in cardiovascular and renal complications, through processes mediated by both direct target tissue insults and indirectly, by hypertension. PA spans a continuum of dysregulated aldosterone secretion, which is typically recognized in late stages after treatment-resistant hypertension and cardiovascular and/or renal complications develop. Determining the precise disease burden remains challenging due to heterogeneity in testing, arbitrary thresholds, and populations studied. This review summarizes the reports on PA prevalence among the general population and in specific high-risk subgroups, highlighting the impact of rigid versus permissive criteria on PA prevalence perception.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, USA. Ann Arbor, Michigan.
- Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Khon Kaen University, Thailand.
ORCID-Profile: Adina F Turcu
Förderung
- NHLBI NIH HHS
- Doris Duke Charitable Foundation
- National Heart, Lung, and Blood Institute
Zitieren
APA
Charoensri, S., & Turcu, A. F. (2023). Primary Aldosteronism Prevalence – An Unfolding Story. Experimental and Clinical Endocrinology & Diabetes, 131(07/08), 394-401. https://doi.org/10.1055/a-2066-2696
Vancouver
Charoensri S, Turcu AF. Primary Aldosteronism Prevalence – An Unfolding Story. Experimental and Clinical Endocrinology & Diabetes. 2023;131(07/08):394-401. doi:10.1055/a-2066-2696
BibTeX
@article{Charoensri2023,
author = {Charoensri, Suranut and Turcu, Adina F},
title = {Primary Aldosteronism Prevalence – An Unfolding Story},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2023},
volume = {131},
number = {07/08},
pages = {394--401},
doi = {10.1055/a-2066-2696}
}
EUVIMED